Toon Stegmann involved in India Politics :)
Department of Pharmaceutical Sciences, C.T. Group of Institutes, Shahpur campus, Jalandhar, Punjab, India
ABSTRACT
Vaccine development has continuously shifted away from live attenuated or
inactivated whole organisms. Although this approach having good efficacy
but for improvement on comparison of risk/benefit ratio which needs
improvement due to their highly complex compositions which result in safety
concerns. As a consequence, a number of indications remained unadressed.
The next generation vaccines represented as subunit vaccines, whereby the
only pathogens fragments used which are relevant in inducing protective
immunity. For the successful subunit vaccination two major key
requirements are safe carrier and adjuvant system, since the small, isolated
pathogen fragments themselves are generally weak immunogens. Pevion’s
virus-like particle (VLP) vaccine technology, called virosomes, and their
design is specifically for the development of safe and effective subunit
vaccines. Virosomes based vaccination has already been approved in more
than 40 countries, including for elderly and infants. It is successful in solid
regulatory & safety track record as well as the feasibility of production
upscaling. The outstanding profile with combined efficacy and safety of
virosomes-based vaccines are known for its origin in the unique mode of
action of these multifunctional particles. It leads to a comprehensive
induction of a complete immune response, in contrast to single-sided
triggers. Virosomes are reconstituted viral envelopes that can serve as
vaccines and as vehicles for cellular delivery of macromolecules. The
prospect of drug delivery and targeting using virosomes is an interesting field
of research and development. As virosomes are biocompatible,
biodegradable, nontoxic, and non-autoimmunogenic, and various attempts
have been made to use them as vaccines or adjuvants as well as delivery
system for drugs, nuleic acids, nucleic acids, or genes for therapeutic
purposes. The virus of choice is influenza virus. Virosomal drug delivery
depends on the methods used to prepare the encapsulated bioactive
material their incorporation into the virosomes, and followed by the
characterization and formulation of the finished preparations. This
technology can potentially be used to deliver peptides, nucleic acids or
genes, and drugs like antibiotics, anticancer agents, and steroids. In this
paper reviewed about the advantages of virosomes in successful delivery of immunogens
Market Data 
Markets 
AI
